Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term outcome for lymph node-positive prostate cancer.

G P Swanson1, M W Riggs, M Herman

  • 1The Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. gswanson@ctrc.net

Prostate Cancer and Prostatic Diseases
|May 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding the high-resolution spectral signature of the N2-H2O van der Waals complex in the 2OH stretch region.

The Journal of chemical physics·2023
Same author

MRI in the assessment of thyroid-associated orbitopathy activity.

Clinical radiology·2022
Same author

Spectroscopic study of the tunneling dynamics in N<sub>2</sub>-water observed in the O-D stretch region.

The Journal of chemical physics·2021
Same author

Fibroblast growth factor 21 and fructose dynamics in humans.

Obesity science & practice·2018
Same author

Intraneural Ganglion Cyst of the Tibial Nerve.

Journal of the Belgian Society of Radiology·2018
Same author

Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: randomized placebo controlled clinical trial.

European journal of clinical nutrition·2017
Same journal

Focal therapy for localized prostate cancer: not all that glitters is gold.

Prostate cancer and prostatic diseases·2026
Same journal

A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.

Prostate cancer and prostatic diseases·2026
Same journal

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

Prostate cancer and prostatic diseases·2026
Same journal

Response to de Riese et al. regarding "methodological and clinical considerations of MRI-based prostate cancer risk calculators".

Prostate cancer and prostatic diseases·2026
Same journal

Methodological and clinical considerations of MRI-based prostate cancer risk calculators.

Prostate cancer and prostatic diseases·2026
Same journal

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
See all related articles

Long-term follow-up of men with lymph node-positive prostate cancer shows 10-year survival is 56%. Adding androgen ablation improves tumor control duration, but optimal timing requires further study.

Area of Science:

  • Oncology
  • Urology

Background:

  • Lymph node-positive prostate cancer, while declining, still presents a significant treatment challenge.
  • Long-term outcomes are crucial for evaluating prostate cancer treatment efficacy.

Purpose of the Study:

  • To evaluate the long-term outcomes of treating men with lymph node-positive prostate cancer.
  • To assess the impact of treatment strategies on survival and tumor control.

Main Methods:

  • Retrospective analysis of patients with lymph node-positive prostate cancer.
  • Median follow-up duration of 10.2 years.
  • Survival rates and tumor control duration were analyzed.

Main Results:

  • Overall 5-year survival rate was 78%.

Related Experiment Videos

  • Overall 10-year survival rate was 56%.
  • Androgen ablation significantly improved the duration of tumor control.

    • Conclusions:

    • Long-term survival for lymph node-positive prostate cancer remains a challenge.
    • Androgen ablation is a key treatment modality for improving tumor control, though its optimal timing needs further investigation.